This is a preview of subscription content, log in via an institution to check access.
Notes
see PharmacoEconomics & Outcomes News 737 p2; 801085982
PCSK9 Inhibitors for Treatment of High Cholesterol: Effectiveness, Value, and Value-Based Price Benchmarks
CardioMEMS HF System (St. Jude Medical) and Sacubitril/Valsartan (Entresto, Novartis) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks
References
, et al. ICER issues revisions to two value-based draft reports PharmacoEconomics and Outcomes News : Oct 2015
Institute for Clinical and Economic Review. ICER Releases Revised Draft Report on CardioMEMS? HF System and Entresto for Management of Congestive Heart Failure, Subject of October 29 CTAF Meeting . Internet Document : Oct 2015. Available from: URL: http://www.icer-review.org/chf-revised-draft-released/
Institute for Clinical and Economic Review. ICER Releases Revised Draft Report: PCSK9 Inhibitors for Treatment of High Cholesterol: Effectiveness, Value, and Value-Based Price Benchmarks, Subject of October 27 CEPAC Meeting . Internet Document : Oct 2015. Available from: URL: http://www.icer-review.org/icer-releases-revised-draft-report-pcsk9-inhibitors-for-treatment-of-high-cholesterol-effectiveness-value-and-value-based-price-benchmarks-subject-of-october-27-cepac-meeting/
Rights and permissions
About this article
Cite this article
ICER issues revisions to two value-based draft reports. PharmacoEcon Outcomes News 739, 2 (2015). https://doi.org/10.1007/s40274-015-2520-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2520-0